00:00
Biotest AG, BT-062: A Potent Antibody-Drug Conjugate for the Treatment of CD138 Expressing Tumors
00:15
Biotest Group,
Headquarters, Subsidiaries, Employees, Biotest shares, Financials, Biotest Group
00:55
Plasma Proteins, Biotherapeutics, Immunoglobulins, Hyper- Immunoglobulins, Clotting factors, Human Albumin, Monoclonal Antibodies, BT 061, BT 062, BT 063, Clinical Development, Production at BPC, License Agreement
, Biotest: a specialized pharmaceutical company
02:05
Multiple Myeloma, Forecast, hematologic malignancy , Multiple Myeloma: Overview
03:00
Myeloma Current Treatment, Stem cell transplant candidates, Thalidomide, dexamethasone 1, Velcade, dexamethasone, Velcade, doxorubicin, dexamethasone, Thalomid, Velcade, liposomal doxorubicin, Revlimid, dexamethasone, Drugs in clinical development
, Multiple Myeloma: Current Treatment Overview
04:00
Efficacy Issues, drug toxicities, multiple myeloma, The Most Significant Unmet Needs in Multiple Myeloma Arise from Safety and Efficacy Issues
04:34
Multiple Myeloma Market, Novel Agents, Revlimid, Velcade, Thalomid, Multiple Myeloma Market (7MM)1 - Growth Driven by Increased Uptake of 'Novel Agents'
06:00
BT-062 Market Opportunity, Relapsed, Refractory, BT-062
, BT-062 Market Opportunity in Relapsed, Refractory Multiple Myeloma
06:22
potent Antibody-Drug Conjugate, Multiple Myeloma, Tumor-targeting, CD138, BT-062: A potent Antibody-Drug Conjugate for Treatment of Multiple Myeloma
07:53
BT-062, Mode of Action, Binding, Internalization, Binding to CD138, Receptor, polymerization
, BT-062: Mode of Action
08:58
Conjugate Optimization, Efficacy, BT-062-mediated, Xenograft model, toxin-linker, BT-062: Improved Efficacy after Conjugate Optimization
10:45
Clinical Development, Monotherapy, Revlimid, Result
, BT-062: Clinical Development in Multiple Myeloma
11:54
Study 969, Clinical Benefit, Monotherapy Study, , Study 969: Clinical Benefit Shown in a Dose Finding Phase I Multiple Myeloma Monotherapy Study
12:58
serum FLC, oligo-secretory Multiple Myeloma, , BT-062: Repeated Single Dose Study 969
13:50
Intensification of Exposure, Phase I/IIa, monotherapy, , Study 975: Intensification of Exposure by More Frequent Dosing - Study Ongoing
14:29
Rationale for Clinical Development, Solid Tumor Indications, CD138 expression, mammary, prostate, lung, head and neck, bladder, and pancreatic carcinoma, clinical study, BT-062: Rationale for Clinical Development in Solid Tumor Indications
15:06
BT-062 in Solid Tumor Indications, remission, carcinoma xenograft, HER2-negative, triple negative breast cancer, BT-062 in Solid Tumor Indications
16:10
BT-062: Development Plan and Milestones, Mono therapy,
Combination therapy, Efficacy, BT-062: Development Plan and Milestones
